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Abstract
Background:  Pneumocystis pneumonia (PCP) is an increasing problem amongst patients on
immunosuppression with autoimmune inflammatory disorders (AID). The disease presents acutely
and its diagnosis requires bronchoalveolar lavage in most cases. Despite treatment with
intravenous antibiotics, PCP carries a worse prognosis in AID patients than HIV positive patients.
The overall incidence of PCP in patients with AID remains low, although patients with Wegener's
granulomatosis are at particular risk.
Discussion: In adults with AID, the risk of PCP is related to treatment with systemic steroid, ill-
defined individual variation in steroid sensitivity and CD4+ lymphocyte count. Rather than opting
for PCP prophylaxis on the basis of disease or treatment with cyclophosphamide, we argue the case
for carrying out CD4+ lymphocyte counts on selected patients as a means of identifying individuals
who are most likely to benefit from PCP prophylaxis.
Summary:  Corticosteroids, lymphopenia and a low CD4+ count in particular, have been
identified as risk factors for the development of PCP in adults with AID. Trimethoprim-
sulfamethoxazole (co-trimoxazole) is an effective prophylactic agent, but indications for its use
remain ill-defined. Further prospective trials are required to validate our proposed prevention
strategy.
Background
Pneumocystis carinii was identified a hundred years ago
by Chagas [1] and recognised as a pathogen in marasmic
children at the end of World War II [2]. The organism
came to the fore again in the early 1980s when apparently
healthy homosexual men developed PCP and heralded
the acquired immunodeficiency syndrome (AIDS) epi-
demic [3]. With highly active antiretroviral therapy
(HAART) and prophylactic antibiotics, attention has
turned to PCP in human immunodeficiency virus (HIV)
negative individuals. We recently treated a young woman
with steroid-based immunosuppression for dermatomy-
ositis. Four months after diagnosis, she was admitted
acutely breathless to the intensive care unit with a pre-
sumptive diagnosis of PCP. Although the final diagnosis
was rapidly progressive alveolitis related to dematomyosi-
tis, it prompted us to consider whether we should use PCP
prophylaxis for selected patients receiving systemic ster-
oids for AID. In this article we explore the background of
PCP in HIV negative patients, consider the incidence of
PCP in AID, discuss predisposing factors and propose a
strategy for prevention.
Published: 16 October 2004
BMC Infectious Diseases 2004, 4:42 doi:10.1186/1471-2334-4-42
Received: 02 June 2004
Accepted: 16 October 2004
This article is available from: http://www.biomedcentral.com/1471-2334/4/42
© 2004 Sowden and Carmichael; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2004, 4:42 http://www.biomedcentral.com/1471-2334/4/42
Page 2 of 6
(page number not for citation purposes)
Epidemiology
Pneumocystis pneumonia is caused in humans by the
recently renamed Pneumocystis jiroveci (Frenkel 1999),
previously known as Pneumocystis carinii and now
thought to be related to fungi on the basis of DNA analy-
sis, despite morphological similarities to protozoa [4].
The organism shows significant genetic divergence and is
host specific with no cross-species infectivity. There has
been considerable debate about the nature of the relation-
ship between humans and P. jiroveci. At one time it was
hypothesised that infection occurred through reactivation
of colonisation acquired in childhood, as specific anti-
body was found in seven out of eight normal adults [5].
This suggestion has been refuted by the absence of detect-
able P. jiroveci in bronchoalveolar lavage specimens from
healthy volunteers, despite amplification by the polymer-
ase chain reaction [6]. In addition, genotypic analysis of P.
jiroveci from infected adults identified strains found in
patients' place of residence, rather than their place of birth
[7]. Investigation of apparent clusters has shown different
genetic strains affecting most cases, indicating that trans-
mission from affected cases to susceptible persons does
not account for the majority of infections [8,9], despite
the recognised transmission of Pneumocystis DNA from
affected patients to their immunocompetent contact
health care workers to produce colonisation [10]. As P.
jiroveci has been isolated in samples of air [11] and pond
water [12], it is likely that the environment represents the
main source of infection for most patients. Nevertheless,
isolation of known cases of PCP is advisable.
Pneumocystis pneumonia is almost always exclusive to
immunocompromised hosts. Two thirds of cases occur in
HIV positive patients and constitutes the initial manifesta-
tion of AIDS in 46% of these patients [13]. A third of cases
arise in HIV negative patients [14], a group consisting of
organ transplant recipients (0–75%), haematological
malignancies (9–58%), solid organ tumours (4–17.5%)
and AID, usually on immunosuppressive treatment. The
latter group accounts for 13–36% of cases in HIV negative
patients [15-19]. It is this group we wish to consider in
more detail.
Pathogenesis
P. jiroveci trophozoites proliferate and attach to type I
alveolar pneumocytes causing desquamation, leading to a
foamy eosinophilic exudate visible on hematoxylin-eosin
staining and a "honey comb" appearance of lung tissue.
Both antibody and cell mediated immunity have been
postulated as being involved in host protection [20].
Clinical presentation
HIV-negative patients with PCP are older (48–61 years)
than HIV positive patients. Males are affected more often
than females (male to female ratio 1:1.4). The clinical
course is typically more acute, with an average duration of
6–13 days. The most frequent clinical symptoms are dys-
pnoea (63–100%), cough (55–74%), weakness (47%),
loss of appetite (38%) expectoration (22–25%), sweating
(19%), weight loss (13%), haemoptysis (9%) and tho-
racic pain (9%). Physical findings include fever >38°C
(63–85%), râles (55–66%), tachycardia (25%) and tach-
ypnoea (22%). Chest radiography may show bilateral
abnormalities (68–88%), interstitial opacities (64–80%)
and alveolar opacities (31–47%), but may be normal (5–
7%) [14-16,18,21]. The clinical picture can be altered by
the use of aerosolised pentamidine prophylaxis, resulting
in extra-pulmonary disease [20]. P. jiroveci in HIV nega-
tive patients is associated with concurrent pulmonary
infections in over 50% of cases. The implicated pathogens
include Cytomegalovirus (35%), Candida (18%) and
Mycobacterium tuberculosis, which contribute signifi-
cantly to the mortality of PCP [17,18,22].
Diagnosis
P. jiroveci infection is diagnosed in most cases by bron-
choalveolar lavage, which, depending on the staining
method used, has been reported to have a sensitivity of 81
to 90% and a specificity of 90 to 100% [23]. Other meth-
ods used include hypertonic saline induced sputum pro-
duction, which is less sensitive, and definitive open lung
biopsy. Cysts or trophozoites are morphologically identi-
fied by methenamine-silver nitrate or giemsa stains
respectively. Immunospecific stains are now available and
have increased the sensitivity of detection in sputum and
bronchoalveolar lavage fluid [24]. The number of organ-
isms in diagnostic specimens is high in HIV positive
patients, but often low in HIV negative cases. An induced
sputum sample may therefore be insufficient in the latter
situation and bronchoalveolar lavage and/or transbron-
chial biopsy is the preferred method of investigation [20].
In patients who are at risk of PCP it is essential to have a
high index of suspicion and low threshold for investiga-
tion, to allow early diagnosis and treatment. This is partic-
ularly important in those with AID, as PCP may mimic
pulmonary involvement by the underlying condition,
such as dermatomyositis, as exemplified by our patient
who prompted this review. In SLE, 33% of patients die
from infections, with 62.5% of all fatal infections being
opportunistic, but only 10% of opportunistic pathogens
are detected ante-mortem [25].
Management
Two antibiotic regimes have been shown to work, co-tri-
moxazole and parenteral pentamidine isethionate. Effica-
cies are comparable, although side-effects are particularly
common with co-trimoxazole in HIV associated PCP and
affect up to 60% of such patients [26]. These include rash,
neutropenia, gastrointestinal upset and liver enzyme dis-
turbance. Although side-effects are less common withBMC Infectious Diseases 2004, 4:42 http://www.biomedcentral.com/1471-2334/4/42
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parenteral pentamidine, toxicity tends to be more severe
and includes pancreatitis, hypoglycaemia, neutropenia,
thrombocytopenia and orthostatic hypotension. Treat-
ment with co-trimoxazole is usually given for 21 days in
HIV cases and 14 days in HIV negative PCP. Co-trimoxa-
zole is used in 90% of cases of PCP [15] and is associated
with fewer reactions (15%) in HIV negative patients [22].
Prognosis
The prognosis of HIV negative PCP is worse than for those
HIV positive, with intensive care admission in 31–60%;
mechanical ventilation in 14–64%; overall mortality 19–
47%, rising to 50–71% on intensive care, although some
series suggest an improved mortality in recent years [14-
18,27]. Poor prognosis has been associated with tachyp-
noea, tachycardia, elevated C-reactive protein, raised lac-
tate dehydrogenase, mechanical ventilation, and some
studies suggest a correlation with previous mean steroid
dose and treatment with cyclophosphamide [17,18]. The
mortality rate of patients with underlying AID appears to
be worse than for other HIV negative patients [15] and
varies according to underlying pathology: 63% in Wege-
ner's granulomatosis; 58% in inflammatory myopathy;
48% in polyarteritis nodosa; 31% in rheumatoid arthritis
and 17% in systemic sclerosis [27]. Several case reports
suggest that PCP in inflammatory myopathy may follow a
fulminant course [28].
While PCP in HIV positive patients has been associated
with a high incidence of relapse after successful therapy,
this has not been seen in patients with AID, even without
secondary prophylaxis and despite ongoing immunosup-
pressive treatment. This is thought to be related to better
clearance of organism, confirmed by repeat bronchoalve-
olar lavage [22].
Incidence
There is no specific surveillance system in the United
Kingdom (UK) for PCP, other than in HIV infection.
Although laboratories are invited to report isolates of P.
jiroveci to the Communicable Disease Surveillance Cen-
tre, it is estimated that only a fifth of clinically diagnosed
cases of PCP are reported [29]. As the laboratory-reported
number of cases was 0.36 per million in 1999, we would
estimate the true incidence of PCP to be approximately
1.8 per million in that year. While Pneumocystis is the
second commonest reported invasive mycosis, this esti-
mate suggests that PCP is still a rare pathogen in the UK.
The overall incidence of PCP from 1990 to 1999 has
declined in the UK [29], as a result of the advent of HAART
for AIDS. However, probably as a result of the use of ever
more immunosuppressive therapy, the number of cases of
PCP diagnosed in HIV negative patients increased
throughout the 1980s and 1990s [14-16,18,27]. These
two opposing trends have resulted in HIV negative
patients constituting an ever increasing proportion of the
total number of cases of PCP.
Attempts have been made to characterise the incidence of
PCP amongst patients with AID, usually by retrospective
analysis of case records. Ward & Donald's review of 223
cases of PCP in AID is the largest series and covered 2.6
million hospitalisations over the period 1983 to 1994
[27]. They found the underlying AID in this group to be
SLE (42%), rheumatoid arthritis (18%), Wegener's granu-
lomatosis (14%), inflammatory myopathy (12%), polyar-
teritis nodosa (9%) and systemic sclerosis (5%). An
estimate of the incidence of PCP in a particular AID was
derived by determining the number of cases of PCP in a
particular AID per 1,000 hospitalisations with the said
AID per year. The results were: 8.9/1,000 hospitalisations
/year for Wegener's granulomatosis; 6.5 for polyarteritis
nodosa; 2.7 for inflammatory myopathy; 1.2 for SLE; 0.8
for systemic sclerosis and 0.2 for rheumatoid arthritis.
Clearly the denominator in these frequencies reflects hos-
pital admissions per year with a particular AID. For an
AID where the average annual rate of admission is less
than once per year, the true incidence for that condition
will be less than the rate quoted and vice versa. These fre-
quencies, with the exception of polyarteritis nodosa, are
broadly comparable with findings in other studies which
report a long-term risk of PCP of 6–12% for Wegener's
granulomatosis and less than 2% for other AID
[14,22,30]. There are only a few isolated reports of PCP in
dermatoses treated with medium-term systemic steroids
such as pemphigus, pemphigoid, cutaneous necrotizing
vasculitis and Behçet's syndrome [22,31].
Discussion
Pneumocystis pneumonia in AID is unusual in the
absence of steroid treatment. Corticosteroids have been
recently administered in over 90% of cases in most series
[14,17,18,22] and were the sole immunosuppressant in
17–28% of AID patients [18,22]. The median duration of
treatment prior to the diagnosis of PCP is three to four
months. Occurrence within a month of starting treatment
is uncommon, with the exception of inflammatory
myopathies [28,32]. Most cases have taken prednisolone
in excess of 15 mg per day, or equivalent doses of corticos-
teroid. Notable is the profound inter-subject variation in
response to standard steroid doses as measured by in vitro
inhibition of lymphocyte proliferation [33], indicating
that host factors are likely to have a significant, but as yet
ill-defined role. Several mechanisms have been postulated
to explain the role of steroids in promoting the develop-
ment of P. jiroveci including CD4+ lymphocyte depletion
and immune dysfunction [17,30]. Porges et al. found an
association between the risk of PCP and the dose of pred-
nisone used in SLE [32]. Similarly, Hellman et al. foundBMC Infectious Diseases 2004, 4:42 http://www.biomedcentral.com/1471-2334/4/42
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an association between prednisolone dosage and risk of
fatal opportunistic infection in SLE, the commonest cause
of which was P. jiroveci [26]. However, other studies have
failed to show an association between cumulative steroid
dose and risk of PCP [34].
A number of cytotoxic and other immunosuppressive
agents commonly used in the treatment of AID are fre-
quently associated with PCP, including cyclophospha-
mide, azathioprine, methotrexate and ciclosporin [14].
Cyclophosphamide is routinely used in the treatment of
Wegener's granulomatosis and has transformed the previ-
ous one year survival figure of 20% [35] into the present
eight year survival of 80% [36]. Godeau et al. [34] showed
a significant association between cyclophosphamide
cumulative dose and the risk of PCP. However, this was
not an independent factor in multivariate analysis when
lymphopenia was taken into account [19]. In one series
involving 180 patients with Wegener's granulomatosis,
no cases of PCP were identified amongst patients on cyto-
toxic therapy alone (although the authors did not specify
the numbers involved), suggesting a permissive role for
corticosteroids [30].
Data on PCP associated with AID indicates lymphocyto-
penia (<1,000 cells/mm3) is almost a prerequisite, with
91% of patients exhibiting a low lymphocyte count. Fifty
percent of such PCP patients have total lymphocyte
counts of <400 cells/mm3 [22]. The pre-treatment lym-
phocyte count and lymphocyte counts during the first
three months of immunosuppressive treatment in Wege-
ner's granulomatosis have been shown to be predictive for
PCP in multivariate analysis. A total lymphocyte count
<600 cells/mm3 was recorded in ten (83%) of 12 patients
with PCP, but such a low lymphocyte count was recorded
in 11 (34%) of 32 with Wegener's unaffected by PCP [34].
A similar association was found in a prospective study
involving patients with SLE [37]. Porges et al [32] pro-
posed a cut off of total lymphocyte count of <350 cells/
mm3 which captured 4 out of 6 cases with PCP and SLE,
but only 1 of 20 patients with SLE unaffected by PCP.
Information on CD4+ counts, which have been shown to
be highly predictive of the risk of PCP in HIV infected
individuals [38], is less well documented in AID patients.
The issue was addressed by Mansharamani et al [19] who
prospectively observed 171 patients in various risk catego-
ries for PCP, including 22 patients with active PCP. They
found that patients who were at high risk of PCP had sig-
nificantly lower CD4+ counts than patients at low risk.
They noted that 91% of cases of PCP had CD4+ counts
<300 cells/mm3 at the time of diagnosis. Their findings are
echoed by an increased risk of respiratory colonisation by
P.jiroveci in HIV negative patients with CD4+ counts of
<400 cells/ mm3 [39].
Kadoya et al [37] in their study on the occurrence of PCP
in 75 patients with inflammatory myopathy and SLE,
noted a significant association between radiological inter-
stitial pulmonary fibrosis (IPF) and the risk of PCP (8.8%
IPF in non-PCP vs 100% IPF in PCP, p < 0.001). In con-
trast, PCP has only rarely been reported in idiopathic pul-
monary fibrosis [15], indicating that more than systemic
steroids and pulmonary fibrosis are required to put
patients at excessive risk of PCP.
Prevention
Co-trimoxazole is commonly used for PCP prophylaxis in
Wegener's granulomatosis when CD4+ counts are <300
cells/mm3 [15] or even with normal counts in some cen-
tres [21]. This combination of antibiotics has been shown
to be effective prophylaxis when used daily or thrice
weekly at a dose of 960 mg in HIV positive patients [40].
Adverse effects occur in less than 20% of patients, usually
manifesting as a rash, which resolves on temporary dis-
continuation and often does not recur on re-challenge
[41,42].
Apart from Wegener's granulomatosis, identifying
patients with AID who are at risk of PCP has proved a
challenge, as the overall incidence is low. Nevertheless it
remains an important issue, as AID patients contribute a
considerable proportion of cases of PCP in HIV negative
patients (up to 36%) and have a particularly poor progno-
sis, as discussed earlier.
Any method used to select patients for prophylactic treat-
ment needs to be assessed against set standards and have
a high sensitivity and specificity. The standards should
address the percentage of PCP cases captured by the selec-
tion criteria (ideally 100% but in practice >80%) and the
risk of the condition in the selected group (which should
be significant). In HIV patients who meet the criteria for
PCP prophylaxis as set out by the US Public Health Service
[43], the annual risk of PCP is 18% [38]. As the mortality
from PCP in HIV negative patients is approximately dou-
ble that of HIV-positive patients [14-18,27], we would
suggest that an annual risk >9% of PCP would be suffi-
cient to justify prophylaxis.
In the study by Mansharamani et al, their proposed cut off
of <300 CD4+ cells/mm3 would capture 91% of cases of
PCP in all HIV negative patients, but would also include
39–46% of patients on systemic steroids, most of whom
would be unaffected by PCP. Administering prophylaxis
to such large numbers of patients would unnecessarily
expose patients to drug side-effects and potentially
encourage drug resistance. However, analysis of their data
reveals that the subgroup of patients with AID who devel-
oped PCP had CD4+ counts of <250 cells/mm3 and six
out of eight had counts <200 cells/mm3 [19].BMC Infectious Diseases 2004, 4:42 http://www.biomedcentral.com/1471-2334/4/42
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Given the laboratory costs, we would argue in favour of
performing CD4+ counts after one month's immunosup-
pression only on patients who satisfy the following three
screening criteria:
• Steroid dosage >15 mg prednisolone or equivalent/day
• >three months corticosteroid treatment proposed
• total lymphocyte count <600 cells/mm3
A CD4+ count <200 cells/mm3 might then warrant the use
of prophylactic co-trimoxazole, if the annual risk of PCP
in these patients is greater than 9%. Most cases of PCP in
patients with AID would be captured by these criteria,
according to published series.
Clearly, further prospective investigation is required to
gather sufficient data to validate any selection method. To
justify our proposed threshold for prophylaxis we would
need to know the risk of PCP for patients on steroid-based
immunosuppression for AID with CD4+ counts of <200
cells/mm3, information which is currently unavailable.
Summary
P. jiroveci infection in HIV negative patients presents
more acutely and has a worse prognosis. The incidence of
PCP in patients with AID is low, although these patients
still represent a considerable proportion of all HIV nega-
tive cases. It is important to have a high index of suspicion
of PCP when treating AID with steroid based immuno-
suppressive regimes, as early treatment could improve
prognosis. The risk of infection is related to treatment
with systemic steroid, ill-defined individual variation in
steroid sensitivity and CD4+ lymphocyte count. Effective
and relatively safe prophylaxis is available. Rather than
opting for PCP prophylaxis on the basis of disease or treat-
ment with cyclophosphamide, we argue the case for carry-
ing out CD4+ lymphocyte counts on selected patients as a
means of identifying individuals who are most likely to
benefit from PCP prophylaxis. Further prospective trials
are required to validate our proposed prevention strategy.
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